Cargando…

Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib

We aimed to explore symptom severity and adherence to therapy for patients with myelofibrosis treated with ruxolitinib in Bulgaria. It is a prospective, non-interventional study performed at the specialized hospital for active treatment of hematological diseases in Sofia during 2022–2023. Date of di...

Descripción completa

Detalles Bibliográficos
Autores principales: Stoeva, Vera, Petrova, Guenka, Mitov, Konstantin, Tachkov, Konstantin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383504/
https://www.ncbi.nlm.nih.gov/pubmed/37513888
http://dx.doi.org/10.3390/ph16070976
_version_ 1785080926727831552
author Stoeva, Vera
Petrova, Guenka
Mitov, Konstantin
Tachkov, Konstantin
author_facet Stoeva, Vera
Petrova, Guenka
Mitov, Konstantin
Tachkov, Konstantin
author_sort Stoeva, Vera
collection PubMed
description We aimed to explore symptom severity and adherence to therapy for patients with myelofibrosis treated with ruxolitinib in Bulgaria. It is a prospective, non-interventional study performed at the specialized hospital for active treatment of hematological diseases in Sofia during 2022–2023. Date of diagnosis, demographic characteristics, clinical indicators, ruxolitinib dose, and other data points were collected. Clinical indicators were assessed at baseline, in the middle, and at the end of observation. Severity of symptoms was measured with MPN-SAF TSS and adherence to therapy with the Morisky 4 questionnaire six times during the observation. The mean age of diagnosis was 58.5 years, with the average duration of disease of 3 years. Patients’ laboratory results were within physiological ranges, with spleen size experiencing a constant decrease. The average value for the severity of the symptoms per MPN-SAF TSS results decreased significantly, indicating better disease control. The average adherence to therapy did not change and remained high at around 9 points, except for one patient. In conclusion the treatment of myelofibrosis patients with ruxolitinib decreased symptom severity and spleen size. Patients were adherent to the therapy over the observed period, but as treatment duration increases, the risk of adherence decreases.
format Online
Article
Text
id pubmed-10383504
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103835042023-07-30 Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib Stoeva, Vera Petrova, Guenka Mitov, Konstantin Tachkov, Konstantin Pharmaceuticals (Basel) Article We aimed to explore symptom severity and adherence to therapy for patients with myelofibrosis treated with ruxolitinib in Bulgaria. It is a prospective, non-interventional study performed at the specialized hospital for active treatment of hematological diseases in Sofia during 2022–2023. Date of diagnosis, demographic characteristics, clinical indicators, ruxolitinib dose, and other data points were collected. Clinical indicators were assessed at baseline, in the middle, and at the end of observation. Severity of symptoms was measured with MPN-SAF TSS and adherence to therapy with the Morisky 4 questionnaire six times during the observation. The mean age of diagnosis was 58.5 years, with the average duration of disease of 3 years. Patients’ laboratory results were within physiological ranges, with spleen size experiencing a constant decrease. The average value for the severity of the symptoms per MPN-SAF TSS results decreased significantly, indicating better disease control. The average adherence to therapy did not change and remained high at around 9 points, except for one patient. In conclusion the treatment of myelofibrosis patients with ruxolitinib decreased symptom severity and spleen size. Patients were adherent to the therapy over the observed period, but as treatment duration increases, the risk of adherence decreases. MDPI 2023-07-07 /pmc/articles/PMC10383504/ /pubmed/37513888 http://dx.doi.org/10.3390/ph16070976 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Stoeva, Vera
Petrova, Guenka
Mitov, Konstantin
Tachkov, Konstantin
Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib
title Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib
title_full Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib
title_fullStr Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib
title_full_unstemmed Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib
title_short Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib
title_sort study of symptom severity and adherence to therapy of myelofibrosis patients treated with ruxolitinib
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383504/
https://www.ncbi.nlm.nih.gov/pubmed/37513888
http://dx.doi.org/10.3390/ph16070976
work_keys_str_mv AT stoevavera studyofsymptomseverityandadherencetotherapyofmyelofibrosispatientstreatedwithruxolitinib
AT petrovaguenka studyofsymptomseverityandadherencetotherapyofmyelofibrosispatientstreatedwithruxolitinib
AT mitovkonstantin studyofsymptomseverityandadherencetotherapyofmyelofibrosispatientstreatedwithruxolitinib
AT tachkovkonstantin studyofsymptomseverityandadherencetotherapyofmyelofibrosispatientstreatedwithruxolitinib